Rhumbline Advisers Has $5.02 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Rhumbline Advisers boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 323,769 shares of the biopharmaceutical company’s stock after buying an additional 10,805 shares during the period. Rhumbline Advisers’ holdings in Catalyst Pharmaceuticals were worth $5,015,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after acquiring an additional 860,244 shares during the period. Janus Henderson Group PLC lifted its stake in Catalyst Pharmaceuticals by 139.5% during the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock worth $43,445,000 after purchasing an additional 1,587,794 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Catalyst Pharmaceuticals by 1.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,601,797 shares of the biopharmaceutical company’s stock valued at $43,738,000 after purchasing an additional 41,923 shares in the last quarter. Opaleye Management Inc. increased its stake in shares of Catalyst Pharmaceuticals by 4.3% in the 4th quarter. Opaleye Management Inc. now owns 1,257,200 shares of the biopharmaceutical company’s stock valued at $21,436,000 after purchasing an additional 52,200 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Catalyst Pharmaceuticals by 1.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock valued at $19,439,000 after purchasing an additional 22,860 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on CPRX shares. Truist Financial raised their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, August 9th. HC Wainwright lifted their price target on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. Oppenheimer reissued an “outperform” rating and issued a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Citigroup increased their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $29.50.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $20.22 on Monday. The company has a market capitalization of $2.40 billion, a P/E ratio of 37.44, a PEG ratio of 3.10 and a beta of 0.75. The company has a fifty day moving average price of $18.42 and a 200-day moving average price of $16.66. Catalyst Pharmaceuticals, Inc. has a 52-week low of $11.55 and a 52-week high of $20.87.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The business had revenue of $122.71 million during the quarter, compared to analyst estimates of $111.76 million. As a group, sell-side analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the sale, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the transaction, the director now owns 348,874 shares in the company, valued at $7,012,367.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Steve Miller sold 150,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the sale, the insider now owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The disclosure for this sale can be found here. Insiders sold 201,058 shares of company stock worth $4,018,188 over the last ninety days. 11.00% of the stock is owned by insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.